Axa’s Theravance Biopharma TBPH Stock Holding History

Axa’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,700	Closed	-$154K	–	1184
2022 Q4	$154K	Sell	13,700 -139,725	-91%	-$1.47M	﹤0.01%	1102
2022 Q3	$1.56M	Hold	153,425	–	–	0.01%	793
2022 Q2	$1.39M	Sell	153,425 -33,075	-18%	-$305K	0.01%	827
2022 Q1	$1.78M	Sell	186,500 -4,300	-2%	-$42.1K	0.01%	852
2021 Q4	$2.11M	Sell	190,800 -28,000	-13%	-$244K	0.01%	835
2021 Q3	$1.62M	Buy	+218,800	New	+$2.45M	﹤0.01%	897
2016 Q4	–	Sell	-13,841	Closed	-$502K	–	1291
2016 Q3	$502K	Buy	+13,841	New	+$385K	﹤0.01%	1022
2015 Q4	–	Sell	-3,200	Closed	-$35K	–	1487
2015 Q3	$35K	Hold	3,200	–	–	﹤0.01%	1378
2015 Q2	$42K	Buy	+3,200	New	+$49.6K	﹤0.01%	1338

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Axa's TBPH Position: Q1 2023 in Review

Axa sold out of Theravance Biopharma (TBPH) in Q1 2023, closing a stake of 13,700 shares — an estimated $154K sold.

Axa first reported a position in TBPH in Q2 2015 and held it in 9 quarters. The position peaked at $2.11M in Q4 2021. 113 funds tracked by Wall St. Rank hold TBPH as of Q1 2023.

Axa reported no remaining Theravance Biopharma position as of Q1 2023 after selling out during the quarter.
Axa sold 13,700 Theravance Biopharma shares in Q1 2023, an estimated $154K.
Axa first reported a position in Theravance Biopharma in Q2 2015 and held it in 9 quarters.
Axa's Theravance Biopharma position peaked at $2.11M in Q4 2021.
113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.